Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma
Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma
复制标题
DOI：
10.1269/jrr.08043
复制
发表时间：
2009-01-01
影响因子：
2
通讯作者：
Ono, Koji
中科院分区：
文献类型：
--
作者：
Kawabata, Shinji;Miyatake, Shin-Ichi;Ono, Koji
我们评估了一种称为硼中子捕获疗法（BNCT）的肿瘤选择性粒子放射治疗新诊断的胶质母细胞瘤（NDGB）患者的临床结果，特别是与X射线治疗（XRT）相结合。在2002年至2006年期间，我们用BNCT治疗NDGB 21例，同时使用硼卡酸钠和硼苯丙氨酸。前10例仅用BNCT治疗（方案1），最后11例用BNCT治疗，然后用20至30戈伊的XRT治疗（方案2），以减少局部肿瘤复发的可能性。在观察到肿瘤进展之前不应用化疗。与机构历史对照相比，接受BNCT（方案I Plus 2）治疗的患者显示出显著的生存期延长。BNCT在与RTOG-和EORTC-RPA亚类的对应关系中也显示出有利的结果。方案I和方案2的中位生存时间（MST）为15.6个月。对于方案2，MST为23.5个月。主要死亡原因为脑脊液播散和局部复发。我们的改良BNCT方案显示，NDGB患者不仅对那些具有良好预后的患者，而且对那些具有不良预后的患者也有良好的结果。
We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma (NDGB) patients, especially in combination with X-ray treatment (XRT). Between 2002 and 2006, we treated 21 patients of NDGB with BNCT utilizing sodium borocaptate and boronophenylalanine simultaneously. The first 10 were treated with only BNCT (protocol 1), and the last I I were treated with BNCT followed by XRT of 20 to 30 Gy (protocol 2) to reduce the possibility of local tumor recurrence. No chemotherapy was applied until tumor progression was observed. The patients treated with BNCT (protocol I Plus 2) showed a significant Survival prolongation compared with the institutional historical controls. BNCT also showed favorable results in Correspondence with the RTOG- and EORTC-RPA Subclasses. The median Survival time (MST) was 15.6 months for protocols I and 2 together. For protocol 2, the MST was 23.5 months. The main causes Of death were cerebrospinal fluid dissemination as well Lis local recurrence. Our modified BNCT protocol showed favorable results of patients with NDGB not only for those with good prognoses but also for those with poor prognoses.